Volume-independent mechanisms of hypertension in hemodialysis patients: Clinical implications

Seminars in Dialysis

Volumn 17, Issue 4, 2004, Pages 265-269

  Blankestijn, Peter J ^a   Ligtenberg, Gerry ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN II ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CATECHOLAMINE; DEBRISOQUINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IODINE 123; LISINOPRIL; MESSENGER RNA; METOPROLOL; MOXONIDINE; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; RENIN; SODIUM; SPIRONOLACTONE;

ADRENERGIC SYSTEM; ATHEROGENESIS; BLOOD PRESSURE; HEART ARRHYTHMIA; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; PATHOGENESIS; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RESTRICTION;

CATECHOLAMINES; HUMANS; HYPERTENSION; HYPERTENSION, RENAL; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 4243164378     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0894-0959.2004.17324.x     Document Type: Review

References (77)

1. Agarwal R: Systolic hypertension in hemodialysis patients. Semin Dial 16:334, 2003
2. Horl MP, Horl WH: Hemodialysis-associated hypertension: pathophysiology and therapy. Am J Kidney Dis 39:227-244, 2002
3. Mailloux LU: Hypertension in chronic renal failure and ESRD: prevalence, pathophysiology, and outcomes. Semin Nephrol 21:146-156, 2001
4. Morse SA, Dang A, Thakur V, Zhang R, Reisin E: Hypertension in chronic dialysis patients: pathophysiology, monitoring, and treatment. Am J Med Sci 325:194-201, 2003
5. Kim KE, Onesti G, Schwartz AB, Chinitz JL, Swartz C: Hemodynamics of hypertension in chronic end-stage renal disease. Circulation 46:456-464, 1972
6. Blankestijn PJ, Ligtenberg G, Klein IH, Koomans HA: Sympathetic overactivity in renal failure controlled by ACE inhibition: clinical significance. Nephrol Dial Transplant 15:755-758, 2000
7. Neumann J, Ligtenberg G, Klein HH, Koomans HA, Biankestijn PJ: Sympathetic hyperactivity in renal hypertension: pathogenesis, clinical relevance and treatment. Kidney Int 65:1568-1576, 2004
8. Vertes V, Cangiano JL, Herman LB, Gould A: Hypertension in end-stage renal disease. N Engl J Med 280:978-981, 1969
9. Cangiano JL, Ramirez-Muxo O, Ramirez-Gonzalez R, Trevino A, Campos JA: Normal renin uremic hypertension. Study of cardiac hemodynamics, plasma volume, extracellular fluid volume, and the renin angiotensin system. Arch Intern Med 136:17-23, 1976
10. Weidmann P, Maxwell MH, Lupu AN, Lewin AJ, Massry SG: Plasma renin activity and blood pressure in terminal renal failure. N Engl J Med 285:757-762, 1971
11. Mimran A, Shaldon S, Barjon P, Mion C: The effect of an angiotensin antagonist (saralasin) on arterial pressure and plasma aldosterone in hemodialysis-resistant hypertensive patients. Clin Nephrol 9:63-67, 1978
12. van Ampting JM, Penne EL, Beek FJ, Koomans HA, Boer WH, Beutler JJ: Prevalence of atherosclerotic renal artery stenosis in patients starting dialysis. Nephrol Dial Transplant 18:1147-1151, 2003
13. Bongu S, Faubert PF, Porush JG, Gulmi F: Uncontrolled hypertension and hyperreninemia after hemorrhage in a patient with end-stage renal disease and acquired renal cysts. J Am Soc Nephrol 5:22-26, 1994
14. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG: Somatosensory, proprioceptive, and sympathetic activity in human peripheral nerves. Physiol Rev 59:919-957, 1979
15. Sundlof G, Wallin BG: Human muscle nerve sympathetic activity at rest. Relationship to blood pressure and age. J Physiol 274:621-637, 1978
16. Vissing SF, Scherrer U, Victor RG: Relation between sympathetic outflow and vascular resistance in the calf during perturbations in central venous pressure. Evidence for cardiopulmonary afferent regulation of calf vascular resistance in humans. Circ Res 65:1710-1717, 1989
17. Grassi G, Esler M: How to assess sympathetic activity in humans. J Hypertens 17:719-734, 1999
18. Matsukawa T, Gotoh E, Minamisawa K, Kihara M, Ueda S, Shionoiri H, Ishii M: Effects of intravenous infusions of angiotensin II on muscle sympathetic nerve activity in humans. Am J Physiol 261:R690-R696, 1991
19. Reid IA: Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol 262:E763-E778, 1992
20. Ye S, Zhong H, Duong VN, Campese VM: Losartan reduces central and peripheral sympathetic nerve activity in a rat model of neurogenic hypertension. Hypertension 39:1101-1106, 2002
21. Levitan D, Massry SG, Romoff M, Campese VM: Plasma catecholamines and autonomic nervous system function in patients with early renal insufficiency and hypertension: effect of clonidine. Nephron 36:24-29, 1984
22. Laederach K, Weidmann P: Plasma and urinary catecholamines as related to renal function in man. Kidney Int 31:107-111, 1987
23. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 327:1912-1918, 1992
24. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, Wieneke GH, van Huffelen AC, Koomans HA: Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 340:1321-1328, 1999
25. Converse RL Jr, Jacobsen TN, Jost CM, Toto RD, Grayburn PA, Obregon TM, Fouad-Tarazi F, Victor RG: Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest 90:1657-1665, 1992
26. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH: Sympathetic nerve activity in end-stage renal disease. Circulation 106:1974-1979, 2002
27. Klein HH, Ligtenberg G, Neumann J, Oey PL, Koomans HA. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 14:3239-3244, 2003
28. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ: Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 14:425-430, 2003
29. Neumann J, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ: Eprosartan combined with moxonidine normalizes sympathetic hyperactivity in hypertensive chronic renal failure patients. J Am Soc Nephrol 14:20A(abstract), 2003
30. Wever R, Boer P, Hijmering M, Stroes E, Verhaar M, Kastelein J, Versluis K, Lagerwerf F, van Rijn H, Koomans H, Rabelink T: Nitric oxide production is reduced in patients with chronic renal failure. Arterioscler Thromb Vasc Biol 19:1168-1172, 1999
31. Kielstein JT, Boger RH, Bode-Boger SM, Frolich JC, Haller H, Ritz E, Fliser D: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J Am Soc Nephrol 13:170-176, 2002
32. Hansen J, Jacobsen TN, Victor RG: Is nitric oxide involved in the tonic inhibition of central sympathetic outflow in humans? Hypertension 24:439-444, 1994
33. Lepori M, Sartori C, Trueb L, Owlya R, Nicod P, Scherrer U: Haemodynamic and sympathetic effects of inhibition of nitric oxide synthase by systemic infusion of N(G)-monomethyl-L-arginine into humans are dose dependent. J Hypertens 16:519-523, 1998
34. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J, Boger R: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113-2117, 2001
35. Zoccali C, Mallamaci F, Maas R, Benedetto FA, Tripepi G, Malatino LS, Cataliotti A, Bellanuova I, Boger R: Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 62:339-345, 2002
36. Fagugli RM, Reboldi G, Quintaliani G, Pasini P, Ciao G, Cicconi B, Pasticci F, Kaufman JM, Buoncristiani U: Short daily hemodialysis: blood pressure control and left ventricular mass reduction in hypertensive hemodialysis patients. Am J Kidney Dis 38:371-376, 2001
37. Nesrallah G, Suri R, Moist L, Kortas C, Lindsay RM: Volume control and blood pressure management in patients undergoing quotidian hemodialysis. Am J Kidney Dis 42:13-17, 2003
38. Barone FC, Nelson AH, Ohlstein EH, Willette RN, Sealey JE, Laragh JH, Campbell WG Jr, Feuerstein GZ: Chronic carvedilol reduces mortality and renal damage in hypertensive stroke-prone rats. J Pharmacol Exp Ther 279:948-955, 1996
39. Zilch O, Vos PF, Oey PL, Ligtenberg G, Koomans HA, Blankestijn PJ: Daily dialysis reduces peripheral vascular resistance and sympathetic activity [abstract]. J Am Soc Nephrol 12:280A, 2001
40. Kielstein JT, Bode-Boger SM, Frolich JC, Haller H, Boger RH: Relationship of asymmetric dimethylarginine to dialysis treatment and atherosclerotic disease. Kidney Int Suppl 78:S9-S13, 2001
41. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ: Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 12:2427-2433, 2001
42. Wenting GJ, Blankestijn PJ, Poldermans D, van Geelen J, Derkx FH, Man in't Veld AJ, Schalekamp MA: Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important. Am J Cardiol 59:92D-97D, 1987
43. Schohn D, Weidmann P, Jahn H, Beretta-Piccoli C: Norepinephrine-related mechanism in hypertension accompanying renal failure. Kidney Int 28:814-822, 1985
44. Kelm M, Schafer S, Mingers S, Heydthausen M, Vogt M, Motz W, Strauer BE: Left ventricular mass is linked to cardiac noradrenaline in normotensive and hypertensive patients. J Hypertens 14:1357-1364, 1996
45. Greenwood JP, Scott EM, Stoker JB, Mary DA: Hypertensive left ventricular hypertrophy: relation to peripheral sympathetic drive. J Am Coll Cardiol 38:1711-1717, 2001
46. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD: Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108:560-565, 2003
47. Zoccali C, Mallamaci F, Tripepi G, Parlongo S, Cutrupi S, Benedetto FA, Cataliotti A, Malatino LS: Norepinephrine and concentric hypertrophy in patients with end-stage renal disease. Hypertension 40:41-46, 2002
48. Levin A, Djurdjev O, Barrett B, Burgess E, Carlisle E, Ethier J, Jindal K, Mendelssohn D, Tobe S, Singer J, Thompson C: Cardiovascular disease in patients with chronic kidney disease: getting to the heart of the matter. Am J Kidney Dis 38:1398-1407, 2001
49. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int 36:286-290, 1989
50. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE: The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 5:2024-2031, 1995
51. Zoccali C, Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, Seminara G, Stancanelli B, Malatino LS: Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12:2768-2774, 2001
52. Julius S: Corcoran Lecture. Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 21:886-893, 1993
53. Mancia G, Grassi G, Giannattasio C, Seravalle G: Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. Hypertension 34:724-728, 1999
54. Zoccali C, Mallamaci F, Parlongo S, Cutrupi S, Benedetto FA, Tripepi G, Bonanno G, Rapisarda F, Fatuzzo P, Seminara G, Cataliotti A, Stancanelli B, Malatino LS, Cateliotti A: Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation 105:1354-1359, 2002
55. Grassi G, Dell'Oro R, Seravalle G, Foglia G, Trevano FQ, Mancia G: Short-and long-term neuroadrenergic effects of moderate dietary sodium restriction in essential hypertension. Circulation 106:1957-1961, 2002
56. Hirakata H, Iseki K, Onoyama K, Kumagai H, Fujimi S, Omae T: Long-term hemodynamic response to captopril (SQ 14,225) in hypertensive hemodialysis patients. Clin Nephrol 19:87-91, 1983
57. Wauters JP, Waeber B, Brunner HR, Guignard JP, Turini GA, Gavras H: Uncontrollable hypertension in patients on hemodialysis: long-term treatment with captopril and salt subtraction. Clin Nephrol 16:86-92, 1981
58. Agarwal R, Lewis R, Davis JL, Becker B: Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. Am J Kidney Dis 38:1245-1250, 2001
59. Sakata K, Shirotani M, Yoshida H, Kurata C: Comparison of effects of enalapril and nitrendipine on cardiac sympathetic nervous system in essential hypertension. J Am Coll Cardiol 32:438-443, 1998
60. Sakata K, Yoshida H, Obayashi K, Ishikawa J, Tamekiyo H, Nawada R, Doi O: Effects of losartan and its combination with quinapril on the cardiac sympathetic nervous system and neurohormonal status in essential hypertension. J Hypertens 20:103-110, 2002
61. Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M: Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. J Am Coll Cardiol 41:574-581, 2003
62. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, Allan R, Kelly S, Newton GE, Floras JS, Parker JD: Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: differential effects on sympathetic activity. Circulation 104:2194-2199, 2001
63. London GM, Pannier B, Guerin AP, Marchais SJ, Safar ME, Cuche JL: Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 90:2786-2796, 1994
64. Cannella G, Paoletti E, Delfino R, Peloso G, Rolla D, Molinari S: Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 30:659-664, 1997
65. Cannella G, Paoletti E, Delfino R, Peloso G, Molinari S, Traverso GB: Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 44:881-886, 1993
66. Dyadyk AI, Bagriy AE, Lebed IA, Yarovaya NF, Schukina EV, Taradin GG: ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant 12:945-951, 1997
67. Francis GS, Cohn JN, Johnson G, Rector TS, Goldman S, Simon A: Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation 87:VI40-VI48, 1993
68. Efrati S, Zaidenstein R, Dishy V, Beberashvili I, Sharist M, Averbukh Z, Golik A, Weissgarten J: ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 40:1023-1029, 2002
69. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134:629-636, 2001
70. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A, Russo PE, Golino P, Calabro R: Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 41:1438-1444, 2003
71. Foley RN, Herzog CA, Collins AJ: Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 62:1784-1790, 2002
72. Berger AK, Duval S, Krumholz HM: Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 42:201-208, 2003
73. Saran R, Dykstra DM, Wolfe RA, Gillespie B, Held PJ, Young EW: Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 40:1255-1263, 2002
74. Baigent C, Burbury K, Wheeler D: Premature cardiovascular disease in chronic renal failure. Lancet 356:147-152, 2000
75. Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ 326:1419, 2003
76. Wolfrum S, Jensen KS, Liao JK: Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 23:729-736, 2003
77. Pliquett RU, Cornish KG, Peuler JD, Zucker IH: Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 107:2493-2498, 2003